More than half of the older adults in the United States are now taking a daily dose of aspirin,...
Kenneth C. Frazier, chairman and CEO of Merck & Co., Inc., was elected chairman of the Board...
PhRMA honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions” for their extraordinary efforts in policy advocacy and community service.
Stratus Pharmaceuticals marketed and distributed unapproved prescription drug products that were manufactured by Sonar Products, Inc., of Carlstadt, New Jersey.
OriGen Biomedical initiated a nationwide recall for one lot of Reinforced Dual Lumen ECMO catheters.
A measles outbreak that began at Disneyland and reignited debate about vaccinations is nearing an end.
The Food and Drug Administration is warning consumers to avoid dietary supplements sold by a Las Vegas company because they may contain anabolic steroids that can cause liver damage.
Federal health officials say about 200 people have come down with vomiting and diarrhea aboard two San Diego-bound cruise ships.
IDT Australia Limited announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the change of ownership letters formally transferring ownership of the 23 generic drug products to IDT.
The issue also intensified criticisms of the FDA.
The FDA has notified Tekmira that the partial clinical hold on TKM-Ebola has been modified. Tekmira plans to resume the TKM-Ebola Phase I clinical trial in the coming weeks.
Parents of Melinda Ann "Mandy" Fortuna filed suit yesterday against Allergan, Inc., alleging that a series of off-label Botox overdoses were responsible for their daughter's death.
Baxter International Inc. announced today it is voluntarily recalling select lots of IV solutions to the hospital/user level due to the potential presence of particulate matter.
The FDA has granted Fast Track designation to BioBlast's Cabaletta for the treatment of patients with Oculopharyngeal Muscular Dystrophy (OPMD).
Prolong Pharmaceuticals, LLC, a biopharmaceutical company, announced that the FDA has granted Orphan Drug Designation for its Sickle Cell Disease (SCD) treatment.
U.S. health regulators have questions about tobacco maker Swedish Match's bid to become the first to market a smokeless tobacco product as less harmful than cigarettes.
Drug and medical device maker Hospira said that it received a warning letter from the FDA following an Italian factory inspection. The agency said it found problems with procedures that are supposed to prevent sterile products from being contaminated, and found fault with Hospira's inspections procedures. It also said the company should have better security protecting data generated during its manufacturing process.
Officials say an American healthcare worker who contracted Ebola while volunteering in Sierra Leone has improved to good condition at a federal hospital. He is being treated at the NIH hospital in Bethesda, Maryland.
“Precision” drugs are tailored to a cancer’s or a patient’s genetic makeup. Such “precision medicine” is now the focus of a new $215 million research initiative launched this year by U.S. President Barack Obama.
Simulations Plus announced that several regulatory agencies around the world have added licenses of software for pharmaceutical discovery and development within the past three months.
Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug.
HHS awarded approximately $12 million today to BioCryst Pharmaceuticals of Durham, North Carolina, for the advanced development of a promising experimental drug for Ebola, including preparing for large-scale manufacturing of the drug and conducting related studies.
In a move that could heighten the hurdles faced by states attempting to execute prisoners, a leading association for U.S. pharmacists has officially discouraged its members from providing drugs for use in lethal injections.
Federal officials plan to review the safety and evidence behind alternative remedies like Zicam and Cold-Eeze, products that are protected by federal law, but not accepted by mainstream medicine.
Orexigen Therapeutics has announced that the European Commission has granted marketing authorization for Mysimba (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients.
The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era of innovative therapies and big profits.
Sanofi Pasteur, the vaccines division of Sanofi announced that FDAhas approved use of Quadracel vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.
- Page 1